RMD – UBS rates the stock as Neutral

By Broker News | More Articles by Broker News

The company will acquire Propeller Health, a US provider of monitoring devices for those with COPD and asthma. The purchase price is US$225m, to be funded by debt.

UBS believes the transaction make strategic sense as it extends the company’s connected health solutions.

The broker maintains a Neutral rating and raises the target to US$111 from US$107.

Sector: Health Care Equipment & Services.

Current Price is $15.17. Target price not assessed.

 

Broker News

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →